Lausanne cohort of septic patients as an opportunity to develop multidisciplinary research within the Swiss latin network of intensive care medicine;La cohorte sepsis lausannoise une opportunité de développer la recherche dans le Réseau latin

Revue Medicale Suisse

Volumn 4, Issue 183, 2008, Pages 2686-2690

  Que, Y A ^a   Eggimann, P ^a   Liaudet, L ^a   RChiolero ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DATA BASE; HEALTH CARE FACILITIES AND SERVICES; HEALTH SURVEY; HOSPITAL CARE; INTENSIVE CARE; INTENSIVE CARE UNIT; LENGTH OF STAY; MEDICAL RESEARCH; MORBIDITY; MORTALITY; PATHOGENICITY; REVIEW; SEPSIS; SWITZERLAND;

BIOMEDICAL RESEARCH; COHORT STUDIES; COOPERATIVE BEHAVIOR; DATABASES AS TOPIC; DIAGNOSIS, DIFFERENTIAL; HUMANS; INTENSIVE CARE; PILOT PROJECTS; SEPSIS; SHOCK, SEPTIC; SWITZERLAND; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 59249091037     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Sands KE, Bates DW, Lanken PN, et al. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 1997;278:234-40.
2. Martin GS.Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-54.
3. Annane D,Bellissant E,Cavaillon JM. Septic shock Lancet 2005;365:63-78.
4. Albert C, Brun-Buisson C, Burchardi H, et al. Epidemiology of sepsis and infection in ICU patients from an International multicentre cohort study. Intensive Care Med 2002:28:108-21.
5. Bernard GR, Vincent JL, Laterre PF. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001,344:699-709.
6. Manns BJ, Lee H, Doig CJ,Johnson D, Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002:347:993- 1000.
7. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
8. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
9. The acute respiratory distress syndrome network, ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301-8.
10. Rivers E, Nguyen B, Havstad S, et al. Early goal directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77
11. van den Berghe G, Wouters P. Weekers F. et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-67.
12. Annane D, Sebille V, Charpentier C. et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-71.
13. Sprung CL Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-24.
14. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-39.
15. Que YA, Haefliger JA, Piroth L, et al. Fibrinogen and fibronectin binding cooperate for valve infection and invasion in staphylococcus aureus experimental endocarditis. J Exp Med 2005;201:1627-35.
16. Que Y. Haefliger J, Francioli P, Moreillon R Expression of staphylococcus aureus dumping-factor A in lactococcus lactis cremoris using a new shuttle vector. Infect Immun 2000;68:3516-22.
17. Bone RC,.Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992;101:1481-3.
18. Abraham E. Matthay MA Dinarello CA, et al. Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a reevaluation, Crit Care Med 2000; 28:232-5.